Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Onxeo S.A.. (2/17/16). "Press Release: Onxeo to Attend Upcoming Investor Conferences and Medical Meetings". Paris & Copenhagen.

Region Region Paris
  Country France
Organisations Organisation Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO)
  Group Onxeo (Group)
  Organisation 2 Ruth Group, The (TRG)
Products Product SFAF Journée Sectorielle Biotech 2016 Paris
  Product 2 Jefferies 2016 Global Healthcare Conference New York
Index term Index term Onxeo–Oddo: investor conference, 201603 supply service Onxeo SA presents at Oddo Biotech/Medtech Forum in Paris
Persons Person Green, Jospeh (Ruth Group 201506)
  Person 2 Trépo, Nathalie (Onxeo 20511– Investor Relations before Neovacs + Theradiag)

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that senior management will present updates on the Company’s advanced orphan oncology pipeline at the following upcoming investor conferences:

> ODDO Biotech / Medtech Forum – March 31, 2016 in Paris (France)
> SFAF Journée Sectorielle Biotech – May 15, 2016 in Paris (France)
> Jefferies Healthcare Conference – June 7-10, 2016 in New York (U.S.A)
> European Large and Midcap Event – October 5-6, 2016 in Paris (France)

In addition, Onxeo will present at the following medical meetings:
> EASL, The International Liver Congress – April 13-17, 2016 in Barcelona (Spain)
> AACR Annual Meeting 2016 – April 16-20, 2016 in New Orleans (U.S.A)
> ESTRO Annual Meeting 2016 – April 29-May 3, 2016 in Turin (Italy)

Onxeo’s next financial updates will be released on the following dates:
> Full-Year 2015 Results – February 26, 2016 (after the close of market)
> Full-Year 2015 Results and Company Update Analyst Conference Call – February 29, 2016 (6:30 PM CET; dial-in details to be released beforehand)
> Annual SFAF Meeting – March 7, 2016 (11:00 AM CET) in Paris (France)

Investors and analysts interested in scheduling a meeting with Onxeo management or participating in a Company conference call can contact Onxeo’s Investor Relations team ( or Lee Roth and Joseph Green at The Ruth Group (+1 646-536-7012/7013 or /

About Onxeo

Onxeo is a leading developer of orphan oncology drugs. The Company is focused on developing innovative therapeutics for rare cancers, one of the fastest growing markets in the healthcare industry with high, unmet medical needs. Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with three independent programs in advanced clinical development, including Onxeo’s first approved orphan oncology drug, Beleodaq®. In addition, Onxeo has successfully developed and registered two non-cancer products which are currently being commercialized in the U.S. and Europe. Onxeo’s vision is to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, by developing advanced, effective, and safe therapeutics designed to improve the lives of patients. The Company is headquartered in Paris, France and has approximately 50 employees. Onxeo is listed on Euronext in Paris, France (Ticker: ONXEO, ISIN Code: FR0010095596) and NASDAQ Copenhagen, Denmark (Ticker: ONXEO).
Onxeo orphan oncology products at the advanced development stage are:

> Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer);

> Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial in head and neck cancer patients with severe oral mucositis;

> Beleodaq® (belinostat): FDA-approved in the U.S. in 2014 under the agency’s accelerated approval program as a second-line treatment for patients with peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in the U.S., Spectrum Pharmaceuticals; belinostat in combination with CHOP (BelCHOP) is also in development as first-line treatment for patients with PTCL.

For more information, visit the website

To receive our press releases and newsletters, please register on:
Follow us on Twitter: @Onxeo_


This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website ( or on the company’s website (


Nathalie Delair-Trepo
Investor Relations, Onxeo
+ 33 1 45 58 76 00

Caroline Carmagnol and Florence Portejoie – Alize RP (France)
+33 6 64 18 99 59 / +33 6 47 38 90 04

Kirsten Thomas / Lee Roth – The Ruth Group (U.S.) /
+1 508 280 6592 / +1 646 536 7012

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Onxeo (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top